Sum­mit’s dis­ap­point­ing sur­vival read­out rais­es stakes for full da­ta

Sum­mit Ther­a­peu­tics’ mixed re­sults for its po­ten­tial com­peti­tor to Mer­ck’s Keytru­da left an im­por­tant ques­tion unan­swered: How ma­ture, ex­act­ly, were the da­ta?

The biotech on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER